Amylyx Pharmaceuticals. has filed a patent for methods and compositions to treat neurodegenerative diseases like ALS. The treatment involves administering a bile acid or its salt along with a phenylbutyrate compound. GlobalData’s report on Amylyx Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Amylyx Pharmaceuticals Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Amylyx Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Amylyx Pharmaceuticals's grant share as of January 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment for neurodegenerative disease using bile acid and phenylbutyrate

Source: United States Patent and Trademark Office (USPTO). Credit: Amylyx Pharmaceuticals Inc

A recent patent application (Publication Number: US20230372263A1) discloses a method for treating symptoms of Amyotrophic Lateral Sclerosis (ALS) using a specific composition. The method involves administering doses of a composition containing Taurursodiol (TURSO) and sodium phenylbutyrate to the subject at specific times in relation to food consumption. The dosage is determined based on the subject's plasma concentration levels of sodium phenylbutyrate and phenylacetate, with additional doses administered accordingly. The method aims to alleviate ALS symptoms by regulating the plasma concentration of these compounds within specified ranges.

Furthermore, the patent application outlines a method for increasing the plasma concentration of bile acids in a subject by administering a composition containing TURSO and sodium phenylbutyrate. The bile acids can include TURSO, UDCA, or GUDCA, with specific plasma concentration ranges targeted for each type. The administration of the composition can be done once or twice a day for varying durations, with plasma concentration levels monitored to ensure efficacy. The method offers a potential treatment option for individuals looking to increase their bile acid levels through a specific dosage regimen tailored to their needs.

To know more about GlobalData’s detailed insights on Amylyx Pharmaceuticals, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies